| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Cell and Molecular Biology Section,*
Pediatric
Oncology Branch, National Cancer Institute, National Institutes of
Health, Bethesda, Maryland; the Department of
Pathology,
Seoul National University College
of Medicine, Seoul, Korea; and the Department of Nuclear
Medicine,
Samsung Medical Center,
Sungkyunkwan University, Seoul, Korea
The types of neurotrophin receptors that are expressed in neuroblastomas have different prognostic implications; trkA is a marker of good prognosis, whereas trkB expression is associated with poor prognosis. This suggests that either the signaling that is mediated via these receptors modulates the biological features of neuroblastoma cells differently, or that distinct lineages of sympathoadrenal precursors have been transformed. In this report, we evaluate the biological effects after activation of trkA or trkB by their major ligands in SH-SY5Y human neuroblastoma cells. Both trkA and trkB induce differentiation, inhibit growth, and promote the survival of cells under conditions of nutrient deprivation. However, the up-regulation of insulin-like growth factor-II (IGF-II) expression is a predominant feature of trkA activation by nerve growth factor (NGF). The growth inhibition induced by blocking the insulin-like growth factor-I receptor suggests that IGF-II is a component of the effector mechanism of trkA activation by NGF in trkA-transfected cells. Although trkA and trkB expression is associated with different prognoses in neuroblastoma, our study indicates that the effects mediated by these receptors in vivo may be quite similar for certain subsets of neuroblastomas.
This article has been cited by other articles:
 |
|
 |
|
  C. J. Thiele, Z. Li, and A. E. McKee On Trk--The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology Clin. Cancer Res., October 1, 2009; 15(19): 5962 - 5967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakamura, K. C. Martin, J. K. Jackson, K. Beppu, C.-W. Woo, and C. J. Thiele Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells. Cancer Res., April 15, 2006; 66(8): 4249 - 4255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Li, J. Jaboin, P. A. Dennis, and C. J. Thiele Genetic and Pharmacologic Identification of Akt as a Mediator of Brain-Derived Neurotrophic Factor/TrkB Rescue of Neuroblastoma Cells from Chemotherapy-Induced Cell Death Cancer Res., March 15, 2005; 65(6): 2070 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Beppu, J. Jaboine, M. S. Merchant, C. L. Mackall, and C. J. Thiele Effect of Imatinib Mesylate on Neuroblastoma Tumorigenesis and Vascular Endothelial Growth Factor Expression J Natl Cancer Inst, January 7, 2004; 96(1): 46 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jaboin, C. J. Kim, D. R. Kaplan, and C. J. Thiele Brain-derived Neurotrophic Factor Activation of TrkB Protects Neuroblastoma Cells from Chemotherapy-induced Apoptosis via Phosphatidylinositol 3'-Kinase Pathway Cancer Res., November 15, 2002; 62(22): 6756 - 6763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W Zumkeller and M Westphal The IGF/IGFBP system in CNS malignancy Mol. Pathol., August 1, 2001; 54(4): 227 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Edsjö, B. Hallberg, S. Fagerström, C. Larsson, H. Axelson, and S. Påhlman Differences in Early and Late Responses between Neurotrophin-stimulated trkA- and trkC-transfected SH-SY5Y Neuroblastoma Cells Cell Growth Differ., January 1, 2001; 12(1): 39 - 50. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
